Citeline Podcasts Citeline

Generics Bulletin's editorial team discusses the latest strategic developments for major industry players Teva, Sandoz and Sawai, as well as explaining the recent debate over US patent listings in the FDA's Orange Book.

Guest speaker Guangzuo Luo, chief scientific officer of Bioncetech, joins China-based editors Brian Yang and Dexter Yan in this episode, which looks at Chinese biotechs going global, and the opportunities and challenges in the latest industry latest trends.
https://scrip.citeline.com/SC150370/China-Biotech-Podcast-Going-Global-Trends-Rare-Disease-Drug-Development

Playlist: https://soundcloud.com/citelinesounds/sets/chinese-language-biopharma?si=80b1209c44874afa9c44bf7d30538320&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing

In an interview with Scrip, JB CEO Nikhil Chopra addresses rumours of a sale of a stake in the Indian pharma/CDMO company by private equity fund KKR, recent acquisitions, including from Novartis, as well as JB's ambitions to ramp up the cardiology segment and its CDMO business, which already has major clients including J&J.
https://scrip.citeline.com/SC150350/Amid-Talk-Of-KKR-Stake-Sale-JB-CEO-Stresses-Business-As-Usual

Audio roundup of selected biopharma industry content from Scrip over the business week ended 31 May 2024. In this episode: ASCO preview; Asahi’s US acquisition; Novartis aims for renal disease dominance; paying for gene therapies; and US BIOSECURE Act diluted.

https://scrip.citeline.com/SC150361/Quick-Listen-Scrips-Five-MustKnow-Things

Playlist: https://soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

An interview with Genmab’s Jan van de Winkel to mark 25 years of the company, and 20 years of the Scrip Awards. A brief history of the antibody-focused biotech company so far, and its plans for future expansion.

In this episode we unpack the Corporate Sustainability Reporting Directive (CSRD) with the help of ESG expert Jasper Crone, drilling down into exactly what consumer healthcare companies need to know about this enormously complex and significant piece of EU legislation.


3:30 Introduction to the CSRD
7:45 What companies are affected by the CSRD
15:00 Specific implications for consumer health companies
21:00 Getting materiality right
25:00 CSRD to do list
32:00 Who’s afraid of targets?
37:00 Who’s responsible for CSRD in companies?
39:00 CSRD and the EU Green Deal
45:00 How will CSRD shape the way companies operate?